The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a phase two trial.
Lucid shares tumble following a public offering of nearly 262.5 million shares
Lucid intends to use the proceeds "for general corporate purposes, which may include, among other things, capital expenditures and working capital."